Puma Biotechnology, Inc. (PBYI)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Puma Biotechnology, Inc. (PBYI) is up 17.3% since the beginning of the year. At $7 per share, PBYI is trading 11.6% below its 52-week high of $8. Investors who bought $1,000 worth of PBYI shares 5 years ago would now be looking at an investment worth $646.

Puma Biotechnology, Inc. (PBYI) has returned 17.31% so far this year and 110.56% over the past 12 months. Over the last ten years, PBYI has returned -15.18% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Apr 24, 2012, PBYI's average daily return is +0.16%, while the average monthly return is +2.83%. At this rate, an investment would double in approximately 2.1 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jul 2014 with a return of +235.9%, while the worst month was May 2019 at -54.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, PBYI closed higher 47% of trading days. The best single day was Jul 23, 2014 with a return of +336.2%, while the worst single day was Nov 2, 2018 at -48.0%.

Puma Biotechnology, Inc. has an annualized alpha of 26.61%, beta of 1.23, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since April 25, 2012.

• This stock participated in 105.48% of S&P 500 Index downside but only 33.54% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PBYI ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Puma Biotechnology, Inc. (PBYI) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Puma Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Puma Biotechnology, Inc. was 99.40%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current Puma Biotechnology, Inc. drawdown is 97.46%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Puma Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Puma Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.